Adicet Bio Inc

NAS:ACET (USA)   Ordinary Shares
$ 1.59 -0.09 (-5.36%) 10:09 PM EST
At Loss
P/B:
0.40
Market Cap:
$ 130.65M
Enterprise V:
$ -742.00K
Volume:
1.60M
Avg Vol (2M):
1.14M
Also Trade In:
Volume:
1.60M
At Loss
Avg Vol (2M):
1.14M

Business Description

Adicet Bio Inc
NAICS : 541714 SIC : 2834
ISIN : US0070021086

Share Class Description:

ACET: Ordinary Shares
Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Name Current Vs Industry Vs History
Cash-To-Debt 7.63
Equity-to-Asset 0.82
Debt-to-Equity 0.12
Debt-to-EBITDA -0.15
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 16.67
9-Day RSI 24.11
14-Day RSI 29.29
6-1 Month Momentum % 86.51
12-1 Month Momentum % -59.76

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.41
Quick Ratio 8.41
Cash Ratio 8.28

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30
Shareholder Yield % -0.57